BR0213424A - Uso aperfeiçoado de composto antitumoral na terapia contra câncer - Google Patents

Uso aperfeiçoado de composto antitumoral na terapia contra câncer

Info

Publication number
BR0213424A
BR0213424A BR0213424-1A BR0213424A BR0213424A BR 0213424 A BR0213424 A BR 0213424A BR 0213424 A BR0213424 A BR 0213424A BR 0213424 A BR0213424 A BR 0213424A
Authority
BR
Brazil
Prior art keywords
cancer therapy
improved use
antitumor compound
improved
compound
Prior art date
Application number
BR0213424-1A
Other languages
English (en)
Inventor
Jose Jimeno
Ana Ruiz Casado
Luis Lopez Lazaro
Eric Rowinsky
Manuel Hidalgo
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR0213424A publication Critical patent/BR0213424A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)

Abstract

"USO APERFEIçOADO DE COMPOSTO ANTITUMORAL NA TERAPIA CONTRA CâNCER". A presente invenção refere-se a programas aperfeiçoados de dosagem de ecteinascidina 743 que são empregados para tratamento de câncer.
BR0213424-1A 2001-10-19 2002-10-21 Uso aperfeiçoado de composto antitumoral na terapia contra câncer BR0213424A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34841401P 2001-10-19 2001-10-19
PCT/US2002/033548 WO2003039571A1 (en) 2001-10-19 2002-10-21 Improved use of antitumoral compound in cancer therapy

Publications (1)

Publication Number Publication Date
BR0213424A true BR0213424A (pt) 2004-12-14

Family

ID=23367939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213424-1A BR0213424A (pt) 2001-10-19 2002-10-21 Uso aperfeiçoado de composto antitumoral na terapia contra câncer

Country Status (15)

Country Link
US (1) US20050004018A1 (pt)
EP (1) EP1435988A4 (pt)
JP (1) JP2005509650A (pt)
KR (1) KR20050038578A (pt)
CN (1) CN1606449A (pt)
AU (1) AU2002343548B2 (pt)
BR (1) BR0213424A (pt)
CA (1) CA2462502A1 (pt)
HU (1) HUP0401903A3 (pt)
IL (1) IL161430A0 (pt)
MX (1) MXPA04003674A (pt)
NO (1) NO20042035L (pt)
PL (1) PL368458A1 (pt)
RU (1) RU2306933C2 (pt)
WO (1) WO2003039571A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
DK1365808T3 (da) * 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
ATE406897T1 (de) 2003-11-13 2008-09-15 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1768671A2 (en) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
ATE430586T1 (de) * 2004-10-26 2009-05-15 Pharma Mar Sa Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20100009906A1 (en) * 2006-05-12 2010-01-14 Pharma Mar, S.A. Anticancer Treatments
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
BRPI0917871A2 (pt) * 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
EP2859893A1 (en) 2010-03-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
WO2013012760A1 (en) 2011-07-15 2013-01-24 Numeta Sciences, Inc. Compositions and methods for modulating metabolic pathways
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
CA2891335C (en) 2012-11-13 2021-05-04 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
PT1280809E (pt) * 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
DK1365808T3 (da) * 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid

Also Published As

Publication number Publication date
IL161430A0 (en) 2004-09-27
CA2462502A1 (en) 2003-05-15
RU2004115110A (ru) 2005-03-10
AU2002343548B2 (en) 2007-11-08
PL368458A1 (en) 2005-03-21
KR20050038578A (ko) 2005-04-27
US20050004018A1 (en) 2005-01-06
AU2002343548B8 (en) 2003-05-19
EP1435988A4 (en) 2008-01-09
NO20042035L (no) 2004-05-18
JP2005509650A (ja) 2005-04-14
CN1606449A (zh) 2005-04-13
MXPA04003674A (es) 2004-07-23
HUP0401903A2 (hu) 2005-01-28
WO2003039571A1 (en) 2003-05-15
EP1435988A1 (en) 2004-07-14
RU2306933C2 (ru) 2007-09-27
HUP0401903A3 (en) 2008-07-28

Similar Documents

Publication Publication Date Title
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
RS48804A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
EE200200263A (et) Telomeeride G-kvadrupleksstruktuuri fikseerivad ühendid, nende kasutamine ja terapeutilised kombinatsioonid
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
BR0310026A (pt) Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
PT1085884E (pt) Combinacao de compostos seleniferos com gemcitabina ou mitomicina c
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
AP2001002274A0 (en) Rescorcinol derivatives.
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
NO970178D0 (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
PT981358E (pt) Derivados de dolastatina-15 em combinacao com taxanos
BR0315489A (pt) Composição antitumorais
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE233745T1 (de) Arzneistoffe
TR200102576T2 (tr) Kanser tedavisinde radyoaktif sisplatin
HK1085744A1 (en) Steroid compounds with anti-tumor activity
TR200302193T4 (tr) Kombinasyon kemoterapisi.
BR0317052A (pt) Composto, métodos para tratar câncer ou doença neoplástica e uma infecção fúngica, para inibir o desenvolvimento de uma célula cancerosa ou célula neoplástica e de um fungo e para induzir a citotoxicidade em uma célula cancerosa ou célula neoplástica, e, composição
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
DK1682107T3 (da) Anti-tumor terpenforbindelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6, DA RPI 2108 DE 31/05/2011.